A Weight Drug for Having Too Little Fat

Lipodystrophy is the opposite of obesity: people with it are missing fat tissue, partially or almost entirely. They also have some of the most severe metabolic disease in medicine — because of the missing fat, not despite it. A cohort of 17 such patients given tirzepatide saw their daily insulin requirement fall by a median of 109 units.^[1]

Why too little fat causes metabolic disease

Fat tissue is not merely storage; it is safe storage. Its job is to hold lipid somewhere it does no harm. When there is not enough of it — through inherited partial lipodystrophy, or generalized forms where fat is nearly absent — the lipid has to go somewhere else.

It goes into the liver, into muscle, into the bloodstream. The result is extreme insulin resistance, triglycerides that can reach thousands, fatty liver disease and diabetes, in people who are frequently lean.

The problem is not too much lipid in the body. It is too little room for it.

Which is why giving a weight-loss drug here is less strange than it sounds. The aim is not to remove fat from someone who has too little. It is to reduce the lipid load that inadequate tissue is being asked to handle.

What happened

Seventeen patients receiving tirzepatide in ordinary clinical care were tracked within natural history studies — 14 with familial partial lipodystrophy, aged 30 to 74 and mostly women, plus three with rarer forms. Median follow-up was 8.7 months.

Read the ranges rather than the medians. A triglyceride fall of 3,820 mg/dL means someone arrived with a level in the thousands — territory where the immediate risk is acute pancreatitis, not long-term cardiovascular disease. And a reduction of 315 units of insulin a day describes a degree of insulin resistance most clinicians will never see.

The BMI column carries the other lesson: the range includes a gain. In a group defined by having too little fat, a modest BMI reduction is not obviously the goal, and one patient went the other way while the metabolic measures still moved.

What seventeen patients can and cannot show

For a disease this rare, seventeen patients is a substantial series — familial partial lipodystrophy affects a few people per million, and a randomized trial in it may never be run. That is a genuine argument for taking a case series seriously here in a way one would not for common obesity.

It is also seventeen people over roughly eight months, and the authors title their own paper with a question mark.

Why it is worth knowing about

• It separates two things these drugs do. Removing fat and reducing lipid load are not the same, and this population makes the distinction visible.
• It is a reminder that body weight is a poor proxy for metabolic health. These patients are often lean and profoundly metabolically ill — the same point from the other direction as beyond BMI.
• Side effects were the ordinary ones. The report describes them as benign gastrointestinal symptoms, with nothing specific to the condition.
• It is off-label, in a rare disease, on a case series — which is how treatment for rare diseases usually begins.